Zealand Pharma Reports Strong H1 2025 Results

Zealand Pharma A/S ( (ZLDPF) ) has released its Q2 earnings. Here is a breakdown of the information Zealand Pharma A/S presented to its investors.

Zealand Pharma A/S, a biotechnology company headquartered in Copenhagen, Denmark, focuses on the discovery and development of innovative peptide-based medicines, with a notable presence in the U.S. market.

In the first half of 2025, Zealand Pharma reported a significant increase in revenue, primarily due to a collaboration with Roche for the development of petrelintide, a promising therapy for weight management. The company also strengthened its leadership team to support future growth and innovation.

Key financial highlights include a revenue surge to DKK 9.1 billion, driven by the Roche partnership, and a robust cash position of DKK 16.6 billion. The company also reported a net result of DKK 7.7 billion, reflecting a strong operational performance. Strategic advancements include the progression of the petrelintide program and positive results from trials of dapiglutide and glepaglutide.

Looking ahead, Zealand Pharma is poised for a catalyst-rich period with upcoming trial results and potential regulatory approvals. The company remains focused on leveraging its strong financial position and strategic partnerships to drive innovation and growth in the biotechnology sector.